- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaPublication without faculty affiliation
- Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR2018 | First Faculty of Medicine
- Multiple myeloma - are we in 2020 able to cure the patient?2020 | First Faculty of Medicine
- Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab2020 | First Faculty of Medicine
- Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma2021 | Faculty of Medicine in Hradec Králové
- Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma2020 | First Faculty of Medicine, Second Faculty of Medicine
- Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies2022 | First Faculty of Medicine